1,721,039 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
Author Under Sail The Imagination of Jack London, 1893-1902
No full textIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Intro -- Title Page -- Copyright Page -- Dedication -- Contents -- Acknowledgments -- Introduction -- 1. Spirit Truth -- 2. From Absorption to Theatricality and Back Again -- 3. "I Will Build a New Present" -- 4. Sons as Authors -- 5. Fathers as Publishers -- 6. The Daughter as Author -- 7. Lovers as Authors -- 8. At Sea with the Family -- 9. Yellow News, Yellow Stories -- 10. The Return Home -- Notes -- Bibliography -- Index -- About Jay WilliamsIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
Devenir des personnes vivant avec le VIH sous une association TRIO dans la cohorte Aquitaine ANRS CO3 : vers une stratégie de simplification thérapeutique ?
No full textObjectives: to assess the long-term follow-up of patients in the ANRS CO3 Aquitaine Cohort treated with a regimen containing etravirine, raltegravir and boosted darunavir (TRIO regimen). Methods: patients from the ANRS CO3 Aquitaine Cohort who were prescribed d a TRIO regimen between February 2007 and September 2018 were included in the present analysis. The primary endpoint was the proportion of patients experiencing virological failure (VF), defined as two plasma viral load (pVL) >50 copies/mL after 24 weeks on the TRIO combination. The secondary endpoints assessed the long-term virological follow-up and the proportion of patients who had a treatment simplification. Results: one hundred and thirty-six patients were included. Baseline plasma viral load (pVL) was above 50 copies /mL for 92(67.6%) patients and below 50 copies /mL for 44 (32.4%). Baseline cumulative resistance genotype showed that 40.8% of patients were resistant to etravirine, 16% to darunavir/ritonavir twice daily and 1.4% to raltegravir Twenty-nine (30.2%) patients experienced VF with resistance associated mutations mainly detected on integrase. The median duration of the follow-up was 7.8 years (InterQuartile Range, 4-9.6) and 27 (19.9%) patients died, including 19 (13.8%) patients under the TRIO regimen. At the last visit, 9 (8.3%) patients were still receiving the TRIO regimen. In opposition, 55 (40.4%) were simplified to dual therapy and 1 (0.7%) to PI-monotherapy. Overall, 96.2% of these patients were virologically suppressed. Conclusion: the long-term virological outcomes were favorable in patients treated with the TRIO regimen, half of them having been eligible for drug-reducing strategies.Introduction : notre étude s’intéresse à l’évolution des personnes vivant avec le VIH (PVVIH) ayant bénéficié d’une association par darunavir boosté par le ritonavir, raltégravir et étravirine (TRIO) dans la cohorte Aquitaine ANRS CO3. La tendance actuelle est à l'allègement thérapeutique. Or, dans les essais cliniques, les PVVIH avec un virus multirésistant ne sont pas inclus. En effet, si la stratégie TRIO a été une alternative thérapeutique de choix chez les patients en échec virologique présentant un virus multirésistant, elle peut néanmoins présenter des inconvénients à long terme sur le risque cardiovasculaire, les interactions médicamenteuses et la dégradation de la qualité de vie due à une prise importante de comprimés par jour. Méthode : étude descriptive non interventionnelle évaluant de manière rétrospective l’évolution virologique et thérapeutique des patients traités par une association TRIO dans la cohorte Aquitaine ANRS CO3 entre Février 2007 et Septembre 2018. L’objectif principal était d’évaluer la proportion de patients en échec virologique sous TRIO, définit par deux charges virales (CV) supérieures à 50 copies/ml à partir du 6ème mois. Les objectifs secondaires étaient de décrire les caractéristiques des patients en échec sous l'association TRIO, d’étudier la réponse virologique tout au long du suivi, d'évaluer la mortalité et la proportion de patient ayant été simplifié. Résultats : cent trente-six patients ont été inclus. La CV était supérieure à 50 copies/mL chez 92 patients (67,6 %) et inférieure à 50 copies/mL chez 44 patients (32,4 %). Le génotype de résistance cumulé à l'inclusion retrouvait une résistance à l'étravirine (ETR) chez 40,8 % des patients, une résistance au darunavir/ritonavir (DRV/r) dans 16 % des cas et une résistance au raltégravir (RAL) dans 1,4 % des cas. Vingt-neuf patients (30,2 %) ont présenté un échec virologique avec des mutations de résistance principalement sélectionnées sur le gène de intégrase. La durée médiane du suivi était de 7,8 ans (IC95%, 4-9,6) et 27 patients (19,9 %) sont décédés, dont 19 (13,8 %) sous l'association TRIO. Lors de la dernière visite, 9 patients (8,3 %) recevaient encore l'association TRIO. En revanche, 55 patients (40,4 %) étaient sous bithérapie et un patient (0,7 %) sous monothérapie de DRV/r. Parmi ces patients allégés, 96,2 % avaient une CV indétectable. Conclusion : cette étude nous a permis d’apprécier l’évolution virologique des personnes vivant avec le VIH ayant bénéficier d’une association TRIO dans la cohorte Aquitaine ANRS CO3. Cette évolution a été favorable et nous avons constatés qu'une proportion importante de patients avait été allégé sur le plan thérapeutique. Ces résultats doivent être compléter par une étude de plus grande ampleur afin d’étudier l’efficacité et la sécurité des stratégies d’allègement chez les patients multirésistants
- …
